Comparison of once-daily mometasone furoate versus once-daily budesonide in patients with moderate persistent asthma

International Journal of Clinical Practice

Volumn 57, Issue 7, 2003, Pages 567-572

  Corren, Jonathan ^a   Berkowitz, R ^b   Murray, J J ^c   Prenner, B ^d  

^a Allergy Research Foundation   (United States)

^b Atlanta Allerg Immunol Res Found   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d Allergy Associates Medical Group Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CORTICOSTEROID; FLUNISOLIDE; FLUTICASONE PROPIONATE; MOMETASONE FUROATE; PLACEBO; SALBUTAMOL; TRIAMCINOLONE ACETONIDE;

ADOLESCENT; ADULT; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; DRY POWDER; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; METERED DOSE INHALER; MULTICENTER STUDY; PEAK EXPIRATORY FLOW; PHARYNGITIS; POWDER INHALER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOM; THRUSH; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS; ASTHMA; BUDESONIDE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FORCED EXPIRATORY VOLUME; HUMANS; MIDDLE AGED; PREGNADIENEDIOLS; RESPIRATORY FUNCTION TESTS; TREATMENT OUTCOME;

EID: 0141837108     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med 1995; 332: 868-875.
2. GINA. Global strategy for asthma management and prevention. Paper presented at: NHLBI/WHO workshop report, 2002, Bethesda, MD.
3. The British Thoracic Society, The National Asthma Campaign, Royal College of Physicians of London in association with the General Practitioner in Asthma Group et al. The British guidelines on asthma management: 1995 review and position statement. Thorax 1997; 52: S1-S21.
4. Cochrane GM, Horne R, Chanez P. Compliance in asthma. Respir Med 1999; 93: 763-769.
5. Venables TL, Addlestone MB, Smithers AJ et al. A comparison of the efficacy and patient acceptability of once daily budesonide via Turbohaler and twice daily fluticasone propionate via disc-inhaler at an equal daily dose of 400 μg in adults asthmatics. Br J Clin Res 1996; 7: 15-32.
6. Campbell LM, Watson DG, Venables TL et al. Once daily budesonide Turbohaler compared with placebo as initial prophylactic therapy for asthma. Br J Clin Res 1991; 2: 111-122.
7. Bender B, Milgrom H, Rand C. Nonadherence in asthmatic patients: is there a solution to the problem? Ann Allergy Asthma Immunol 1997; 79(3): 177-186.
8. Mawhinney H, Spector SL, Kinsman RA et al. Compliance in clinical trials of two nonbronchodilator, antiasthma medications. Ann Allergy 1991; 66(4): 294-299.
9. Coutts JA, Gibson NA, Paton JY. Measuring compliance with inhaled medication in asthma. Arch Dis Child 1992; 67(3): 332-333.
10. Creer TL, Winder JA, Tinkelman D. Guidelines for the diagnosis and management of asthma: accepting the challenge. J Asthma 1999; 36(5): 391-407.
11. Kemp JP, Berkowitz RB, Miller SD et al. Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma. J Allergy Clin Immunol 2000; 106(3): 485-492.
12. Nayak AS, Banov C, Corren J et al. Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma. Ann Allergy Asthma Immunol 2000; 84(4): 417-424.
13. Nathan RA, Nayak AS, Graft DF et al. Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionate. Ann Allergy Asthma Immunol 2001; 86(2): 203-210.
14. Bernstein DI, Berkowitz RB, Chervinsky P et al. Dose-ranging study of a new steroid for asthma: mometasone furoate dry powder inhaler. Respir Med 1999; 93(9): 603-612.
15. Fish JE, Karpel JP, Craig TJ et al. Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma. J Allergy Clin Immunol 2000; 106(5 Pt 1): 852-860.
16. Noonan M, Karpel JP, Bensch GW et al. Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhaler. Ann Allergy Asthma Immunol 2001; 86(1): 36-43.
17. Bousquet J, D'Urzo A, Hebert J et al. Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler. Eur Respir J 2000; 16(5): 808-816.
18. McFadden ER, Casale TB, Edwards TB et al. Administration of budesonide once daily by means of Turbuhaler to subjects with stable asthma. J Allergy Clin Immunol 1999; 104(1): 46-52.
19. Martin RJ, Banks-Schlegel S. Chronobiology of asthma. Am J Respir Crit Care Med 1998; 158(3): 1002-1007.
20. Pincus DJ, Humeston TR, Martin RJ. Further studies on the chronotherapy of asthma with inhaled steroids: the effect of dosage timing on drug efficacy. J Allergy Clin Immunol 1997; 100(6 Pt 1): 771-774.
21. Pincus DJ, Szefler SJ, Ackerson LM, Martin RJ. Chronotherapy of asthma with inhaled steroids: the effect of dosage timing on drug efficacy. J Allergy Clin Immunol 1995; 95(6): 1172-1178.
22. Nayak AS, Banov C, Corren J et al. Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma. Ann Allergy Asthma Immunol 2000; 84: 417-424.